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Abstract 1 
Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease in both adults 2 
and children worldwide.  A disease spectrum, NAFLD progresses from simple steatosis to 3 
steatohepatitis, advanced fibrosis and cirrhosis.  An estimated 20-35% of the general population has 4 
steatosis and 10% of these will develop the more progressive non-alcoholic steatohepatitis 5 
associated with significant increased risk of cardiovascular- and liver-related mortality.  6 
Development of NAFLD is strongly linked to components of the metabolic syndrome including 7 
obesity, insulin resistance, dyslipidaemia and type 2 diabetes.  The recognition that NAFLD is an 8 
independent risk factor for cardiovascular disease is a major public health concern.  There is 9 
tremendous need for a sensitive, non-invasive test for early detection and staging of NAFLD that 10 
could also be used to monitor response to treatment. The cellular and molecular aetiology of 11 
NAFLD is multi-factorial; genetic polymorphisms influencing NAFLD have been identified and 12 
nutrition is a modifiable environmental factor influencing NAFLD progression.  Weight loss 13 
through diet and exercise is the primary recommendation in the clinical management of NAFLD. 14 
The application of systems biology to the identification of NAFLD biomarkers and factors involved 15 
in NAFLD progression is an area of promising research. 16 
 17 
 18 
 3
Introduction 1 
Non-alcoholic fatty liver disease is the pathological accumulation of fat in the liver in the absence 2 
of alcohol intake. Described initially only 30 years ago(1, 2), it is now the leading cause of liver 3 
disease in developed countries with an estimated prevalence of 20-30% in the general population. 4 
The occurrence of non-alcoholic fatty liver disease (NAFLD) is strongly linked to obesity, insulin 5 
resistance and other components of the metabolic syndrome. From a nutrition and public health 6 
perspective, the two major concerns are the rising incidence of NAFLD in children, and the 7 
convincing evidence that NAFLD is an independent risk factor for cardiovascular disease. 8 
The term NAFLD encompasses a spectrum of histologically defined liver disorders. Disease can 9 
progress from macrovesicular lipid accumulation in the hepatocyte known as steatosis, to non-10 
alcoholic steatohepatitis (NASH), steatosis in the presence of inflammatory infiltrate possibly with 11 
some fibrosis, to outright fibrosis, cirrhosis and even hepatocellular carcinoma. A combination of 12 
environmental and genetic factors determines individual risk of NAFLD development and 13 
progression, with a clear role for nutrition as a modifiable environmental risk factor. Pathogenesis 14 
of NAFLD was initially envisaged as a “two-hit process”(3) with fat accumulation in hepatocyte 15 
viewed as the primary insult and increased oxidative stress leading to inflammation being the 16 
second “hit” in progression to NASH and fibrosis.  At the cellular level however, mechanisms 17 
influencing disease progression are clearly multi-factorial and dependent on numerous genetic and 18 
environmental interactions. Future analysis and modeling of NAFLD progression must account for 19 
this complexity in a systems biology fashion. 20 
 21 
Diagnosis 22 
The majority of NAFLD cases are identified after an incidental finding of either elevated liver 23 
enzymes on routine blood tests or suspected fatty liver on abdominal imaging in patients 24 
consuming little or no alcohol.(4)   After the exclusion of excessive alcohol consumption which is 25 
generally defined as more than 20 g/day in men and 10 g/day in women, alternate causes of fatty 26 
liver (nutritional, genetic, viral, metabolic, drug) must also be excluded prior to diagnosis of 27 
NAFLD.  While liver enzymes such as alanine aminotransferase (ALT) and gamma glutamyl 28 
transpeptidase (GGT) levels may be found elevated, they are not specific to NAFLD and 29 
furthermore the full histological spectrum of NAFLD has been observed in patients with normal 30 
ALT levels.(5)  Non-invasive imaging techniques used for diagnosis of NAFLD include ultrasound, 31 
computed tomography, magnetic resonance imaging (MRI) and proton magnetic resonance 32 
spectroscopy (1H MRS), each with its own set of advantages and disadvantages.(6) While all these 33 
techniques yield information about fat distribution in the liver, MRI and 1H MRS can quantify the 34 
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total amount of fat in the liver.  In a population study using 1H MRS to assess liver fat, almost a 1 
third of subjects had hepatic steatosis and 79% of those with steatosis had normal ALT levels.(7)  2 
These data highlight the concern that NAFLD prevalence as assessed by liver enzyme alterations is 3 
grossly under estimated.   4 
Ultrasound-based transient elastography and magnetic resonance elastography are currently 5 
being investigated for their ability to stage liver fibrosis.(8, 9)  However a BMI greater than 28 was 6 
shown to cause transient elastography to fail(10), and  magnetic resonance elastography remains 7 
experimental.(11)   Although algorithms combining biochemical markers and patient parameters 8 
have been developed for predicting steatosis(12), steatohepatitis(13) and fibrosis(14) in NAFLD, these  9 
require independent population validation and still lack sensitivity and specificity for widespread 10 
use. Histological assessment of liver biopsies remains the gold standard for diagnosing and staging 11 
NASH.  However, liver biopsy is invasive and associated with significant morbidities(15) and rare 12 
cases of mortality(16) precluding its routine use in screening for NAFLD or for repeated assessment 13 
of either disease progression or response to therapy.  Furthermore, as histological lesions are not 14 
evenly distributed in the liver, considerable sampling error and misdiagnosis exists.(17)  15 
Consequently, the identification and validation of noninvasive biomarkers capable of diagnosing 16 
and staging NAFLD is a research priority.(18)   17 
 18 
Epidemiology 19 
The lack of an inexpensive, noninvasive screening test for fatty liver disease means the true 20 
population prevalence for NAFLD remains unknown.  Evidence from autopsy(19, 20) and imaging(7, 21 
21, 22) studies demonstrates NAFLD prevalence in 20-35% of populations worldwide with 10% of 22 
these cases being NASH.  Prevalence is much higher among the obese(20, 23-27) and type 2 23 
diabetics(28-30) where NAFLD is found in 70-80% of patients, and advanced disease, NASH and 24 
fibrosis, is found in 25-70% of these cases.  Distinct ethnic differences in the prevalence of NAFLD 25 
exist.(7, 31)  The largest multiethnic population study to date with 2,287 subjects(7), found the highest 26 
frequency of NAFLD in Hispanics (45%) compared to whites (33%) and blacks (24%); a gender 27 
difference was only observed in Caucasians (42% men, 24% women). 28 
 Shockingly, NAFLD is now the most common cause of liver disease in children.   Incidence of 29 
paediatric NAFLD has risen sharply in the last three decades corresponding with the worldwide 30 
increase in childhood obesity.   A retrospective review of paediatric autopsy reports in the United 31 
States found fatty liver in 13% of children and 38% of obese children between 2 and 19 years 32 
old.(32)  Estimates of NAFLD prevalence in obese children using ultrasonography range from 45-33 
60%(33-36), though no survey has been carried out in a UK population.  However, the International 34 
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Obesity Task Force has concluded the lowest estimated prevalence of hepatic steatosis to be 27.9% 1 
among obese children in the European Union.(37)  Of particular concern are very recent datasets 2 
showing that NAFLD in overweight and obese children is not only strongly associated with 3 
cardiovascular risk factors(38), but also atherosclerosis as measured by carotid intima-media 4 
thickness.(39) Since 7% of boys and 10% of girls aged 5-18 in the United Kingdom were obese in 5 
2006(40) (28% and 36% overweight respectively), paediatric NAFLD warrants significant clinical 6 
and research attention. 7 
 8 
 9 
NAFLD development 10 
The pathogenesis of NAFLD begins with accumulation of lipid in the liver.  As only a minority of 11 
patients with hepatic steatosis progress to the necroinflammatory steatohepatitis and develop 12 
fibrosis, Day(3) originally conceptualized that a second “hit” was required to induce cellular events 13 
(e.g. oxidative stress) leading to inflammation, cell death and fibrosis.  As with all complex 14 
diseases, it is now recognized that the phenotypic expression of NAFLD depends on a myriad of 15 
genetic, behavioral and environmental interactions.(41)  16 
While hepatic steatosis can be simplistically viewed as an imbalance between the processes of 17 
lipid accumulation and lipid disposal, the cellular and molecular regulation of hepatic metabolism 18 
is intricate and has been the subject of a recent extensive review.(42) Fat in the liver is acquired from 19 
the diet, de novo lipogenesis or circulating NEFA and removed through VLDL secretion or by β-20 
oxidation.  Derangements in each of these pathways have been associated with NAFLD.   21 
Traditionally it appeared that lipid accumulation in the liver occurred in the context of obesity and 22 
peripheral insulin resistance, with lipid coming from an elevated plasma NEFA pool caused by 23 
increased activity of hormone-sensitive lipase and increased lipolysis from engorged adipocytes. 24 
Multiple lines of evidence suggest this explanation is likely to be too naïve; indeed it has been 25 
postulated that systemic insulin resistance might be secondary to NAFLD. (43) 26 
Stable isotope research in NAFLD patients has shown that, although 60% of the TAG in the 27 
liver comes from the peripheral NEFA pool, elevations in fasting de novo lipogenesis also 28 
contribute significantly.(44) Additional work has observed both an increase in adipose lipolysis, and 29 
increased VLDL-TAG secretion from the liver in NAFLD patients. (45)  However, not only was the 30 
increase in VLDL-TAG secretion not sufficient enough to deal with the increase in hepatic TAG 31 
content in these patients, the VLDL-TAG was derived predominantly from “nonsystemic” NEFA, 32 
either from de novo lipogenesis or lipolysis of visceral fat.  This is interesting in the light of very 33 
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recent 1H-MRS and MRI data showing that hepatic lipid content directly correlates to visceral fat 1 
levels.(46)   This study highlights ethnic differences in the manifestations of insulin resistance; 2 
although Hispanics and African Americans have similar frequencies of insulin resistance, African 3 
Americans are less likely to have NAFLD, hypertriglyceridaemia and elevated visceral fat depots.  4 
These data, as well as data showing NAFLD in nonobese individuals with normal glucose and lipid 5 
levels(47), mean NAFLD can and does occur without the backdrop of insulin resistance. 6 
 Once steatosis is established, multiple mechanisms contribute to lipid-induced cellular injury.(48)  7 
Increased mitochondrial β-oxidation of NEFA leads to an increase in reactive oxygen species 8 
(ROS). Mitochondrial defects have been observed in NAFLD patients and impairment of the 9 
respiratory chain also produces ROS and leads to extra-mitochondrial NEFA oxidation in the 10 
peroxisomes and microsomes producing further ROS.  The overall increase in oxidative stress leads 11 
to lipid peroxidation, DNA and protein damage and ultimately cell death.  In addition the aldehyde 12 
byproducts of lipid peroxidation increase production of proinflammatory cytokines and recruit 13 
inflammatory cells into the liver.   Inflammation and the activation of hepatic stellate cells leads to 14 
collagen production and the initiation of fibrosis. 15 
 Lastly, the pathogenesis of NAFLD is also mediated by transcription factors such as the sterol 16 
regulatory element-binding protein-1 (SREBP1), the carbohydrate responsive element-binding 17 
protein (ChREBP) and the PPARs which are reviewed elsewhere(49), and influenced by circulating 18 
cytokines and adipokines.  Adding additional complexity, the levels of all these molecules will 19 
depend on both genetic polymorphisms and the presence or absence of disease (e.g. obesity or 20 
immune).  Clinical studies reviewed by Tsochatzis and colleagues(50) have shown low levels of the 21 
anti-inflammatory adiponectin and high levels of the pro-inflammatory resistin, TNF-α and IL-6 22 
cytokines in NAFLD patients.  Genetic polymorphisms in these cytokines have also been 23 
investigated in NAFLD patients as described later. 24 
 25 
 26 
NAFLD progression and associated mortality 27 
The prognosis of patients with NAFLD depends on the histological stage of the disease.  Simple 28 
steatosis may have a relatively benign course with no increased risk of mortality, whereas NASH 29 
may progress quite rapidly and is associated with significant increased risk of mortality.(51-54)  30 
Progression in NAFLD is difficult to assess, requiring years of follow up and repeat biopsies which 31 
are prone to sampling errors.(17, 55)  The longest prospective study of the natural history of NAFLD 32 
using repeat biopsies had a mean follow-up of 13.7 years and 129 patients(54).  This study showed 33 
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that 47% of patients presenting with steatosis progressed to NASH and 25-50% of patients 1 
presenting with NASH developed advanced fibrosis or cirrhosis in 8-13 years (Fig. 1).  Although it 2 
underscores the fact that patients with steatosis can and do develop steatohepatitis, mortality was 3 
not changed in the group presenting with steatosis, whereas survival was significantly lower in 4 
patients that had presented with NASH (70% versus 80% in reference population, P = 0.01).  5 
Patients with NAFLD associated cirrhosis have been shown to have a very poor 10 year prognosis, 6 
with 50% needing a liver transplant, 20% dying from a liver-related cause and 7% developing 7 
hepatocellular carcinoma.(56)   Bleakly, a very recent study on the natural history of NAFLD in 8 
children demonstrates that paediatric NAFLD is also progressive and can result in end stage liver 9 
disease and death.(57)  In this cohort of 66 children followed over a mean of 6.4 years, 2 children 10 
underwent liver transplantation and 2 children died, while observed serial biopsies showed 11 
progression in 80% of patients.   12 
Multiple risk factors have been associated with NAFLD progression including older age(23, 24, 58), 13 
BMI(24, 53, 58), insulin resistance(54), diabetes(59, 60), metabolic syndrome(61) and histological NASH 14 
upon diagnosis(52, 54, 62).  A current systematic review of ten studies examined risk factors for 15 
progression from NASH to advanced fibrosis.(63) Using multivariate analysis this study found only 16 
age and presence of inflammation on initial biopsy to independently predict progression in 221 17 
patients over a 5.3 year follow-up.  The well documented limitations associated with systematic 18 
reviews(64), particularly the choice and heterogeneity of included studies in this case, likely explain 19 
why obesity, BMI and diabetes were not statistically significant predictors in this analysis. 20 
 Data regarding the mortality risks associated with NAFLD are somewhat conflicting.  The first 21 
population-based cohort study examining NAFLD and mortality determined survival among 420 22 
NAFLD patients, identified through imaging or biopsy, after a mean follow-up of 7.6 years.(65)  In 23 
agreement with case series from specialist clinics(52, 54, 60), NAFLD was found associated with 24 
significantly lower survival and increased risk of mortality from liver disease.  After 10 years 25 
follow-up (n=161), survival was 77% versus 87% in the general population.    Subsequently 3 26 
independent groups have analyzed data from the Third National Health and Nutrition Examination 27 
Survey (NHANES III) of the United States for mortality risk among suspected NAFLD cases based 28 
on elevated ALT levels.(66-68)  While both Ong(66) and Dunn(67) found NAFLD associated with an 29 
increase in overall mortality, Ong found NAFLD associated with a huge increase in liver associated 30 
mortality, whereas Dunn found NAFLD among 45-54 year olds dramatically linked to 31 
cardiovascular disease (CVD) mortality.  Conversely, Ruhl(68) did not find elevated ALT levels 32 
associated with all-cause or CVD mortality but did find a significant association with liver related 33 
mortality.  Differences are likely explained by variations in study design, patient selection strategy 34 
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and statistical analysis.  While these studies have the advantage of very large samples sizes from a 1 
representative sample of the general population, diagnosis of NAFLD is based on elevated ALT 2 
levels which do not differentiate between steatosis and steatohepatitis and, as previously 3 
mentioned, are likely to severely under assess NAFLD incidence and therefore the magnitude of 4 
mortality risk.  Regardless, the data in total show NAFLD is far from a benign diagnosis. 5 
 6 
 7 
Genetic and environmental factors associated with NAFLD development and progression 8 
The development of NAFLD is strongly linked to obesity and insulin resistance.  However, as there 9 
are obese and diabetic individuals who do not have NAFLD, and since NAFLD can occur in 10 
normal weight individuals with normal glucose and lipid levels(47), there are obviously multiple 11 
genetic and environmental factors determining NAFLD development and progression (Fig. 2).   12 
 Initial evidence for a genetic component to NAFLD comes from familial clustering studies(69, 70) 13 
and the ethnic variation in NAFLD prevalence(7).  Various genetic single nucleotide polymorphisms 14 
(SNPs) have been investigated in NAFLD including SNPs in the adiponectin(71, 72), IL-6(73), TNF-15 
α(74), and apolipoprotein E(75) genes among others.  Investigated in a “candidate gene” fashion in 16 
small cohorts, these studies have yielded somewhat conflicting results in different populations.  In 17 
2008 the first genome-wide association scan in a large multiethnic population targeting NAFLD, 18 
identified the PNPLA3 (Patatin-like phospholipase domain-containing protein 3, also known as 19 
adiponutrin) gene strongly associated with hepatic triglyceride content.(76) Allele variants of the 20 
PNPLA3 gene associated with high and low amounts of hepatic fat were found enriched in 21 
Hispanics and African-Americans respectively, correlating with the high and low prevalence of 22 
NALFD in these populations.(7)  Remarkably, PNPLA3 was also independently identified in a 23 
separate population-based genome-wide scan as one of two genetic loci influencing plasma levels 24 
of ALT.(77) Undoubtedly as genome sequencing continues to get cheaper and faster, studies of this 25 
type will reveal more genes causal in NAFLD pathogenesis. 26 
 Nutrition and physical activity are important environmental factors determining risk of NAFLD.  27 
Excess food intake and lack of exercise contribute to weight gain which has been shown to 28 
contribute to the progression of liver fibrosis in NAFLD patients.(54)  Specific dietary factors may 29 
also play either protective or antagonistic roles in the development and progression of NAFLD.   30 
Assessment of nutrient intakes in NAFLD has been done in Italian(78), Japanese(79), Israeli(80) and 31 
US(81) populations; no UK cohort has been assessed to date.    Increased consumption of meat and 32 
soft drinks and low consumption of fish were associated with NAFLD cases as opposed to control.  33 
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Unsurprisingly, low intakes of PUFA and high intakes of saturated fat and cholesterol were also 1 
associated with NAFLD.  Data from two randomised controlled trial have shown beneficial effects 2 
from six months dietary supplementation with n-3 PUFA in NAFLD compared to dietary advice 3 
alone. (82, 83)   Reductions in fatty liver observed by ultrasonography as well as improvements in 4 
serum ALT and triglyceride levels were significantly greater in those supplemented with n-3 5 
PUFA.  In both trials the patients receiving PUFA were more likely to have complete fatty liver 6 
regression suggesting a beneficial therapeutic effect for n-3 PUFA supplementation in NAFLD.  7 
Other studies have found higher carbohydrate and lower fat diets associated with more progressive 8 
disease.(84, 85) Conversely, very recent animal data alarmingly shows that, in both mice(86) and 9 
nonhuman primates(87), exposure to a maternal high fat diet leads to development and progression 10 
of NAFLD in the offspring.  11 
 Given the role of oxidative stress in NAFLD pathogenesis several studies have examined 12 
antioxidant supplementation as an intervention in NAFLD.  A recent Cochrane review of six very 13 
small and extremely diverse clinical trials did not find enough data to recommend either for or 14 
against the use of antioxidant supplements in NAFLD patients.(88)  However, data from pilot 15 
studies(89, 90) and one double-blind, randomized, placebo-controlled trial(91) have shown sufficient 16 
positive effects with Vitamin E supplementation in NAFLD patients that this supplement is now the 17 
subject of two ongoing multicenter trials.  The “Pioglitazone versus Vitamin E versus Placebo for 18 
the Treatment of Non-diabetic Patients with Non-alcoholic Steatohepatitis” (PIVENS) trial(92) in 19 
adults and the “Treatment of Non-alcoholic Fatty Liver Disease in Children” (TONIC) trial(93) both 20 
involve 96 weeks of treatment and will measure improvements in histology as well as ALT levels.  21 
While the PIVENS trial has 3 arms and includes a placebo group, the TONIC trial in children will 22 
compare metformin treatment to Vitamin E supplementation.   Data from these trials, whether 23 
negative or positive, should end the debate on efficacy of Vitamin E supplementation in NAFLD. 24 
 Small intestinal bacterial overgrowth (SIBO) may be an additional environmental factor 25 
involved in NAFLD pathogenesis where dietary supplements such as probiotics could have a 26 
beneficial effect.   Evidence from animal studies shows that SIBO increases gut permeability 27 
leading to portal endotoxaemia and increased circulating inflammatory cytokines both of which 28 
have been implicated in the progression of NAFLD.(94)  Several reports have found SIBO 29 
associated with progressive NAFLD(95-97) and in one small human study, treatment with antibiotics 30 
resulted in an increase in fasting insulin levels.(97)  Limited evidence from animal models and one 31 
preliminary human study suggest supplementation with the probiotic VSL#3 may possibly be 32 
beneficial in NAFLD, but data is mixed.(98-100)  More research in this area is warranted. 33 
 34 
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  1 
NAFLD, the metabolic syndrome and CVD risk 2 
The metabolic syndrome was originally defined as a cluster of CVD risk factors with insulin 3 
resistance considered the underlying pathogenic factor.(101)  The third report of the National 4 
Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High 5 
Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) defines metabolic syndrome as 6 
being any three or more of five variables: increased waist circumference,  hypertriglyceridaemia, 7 
hypertension, low HDL cholesterol, and hyperglycaemia.(102)  Metabolic syndrome is highly 8 
prevalent among NAFLD patients in multiple populations and is strongly associated with 9 
progressive disease.(61, 103-105)  Equally, a Japanese prospective study (N=3147) demonstrated that 10 
patients with metabolic syndrome, as defined by ATP III, were 4 to 11 times (men and women 11 
respectively) more likely to have developed NAFLD upon follow-up.(106) Likewise, children with 12 
metabolic syndrome as defined by ATP III have been shown to be 5 times more likely to have 13 
NAFLD.(38) This strong relationship between NAFLD and the metabolic syndrome has led to the 14 
description of NAFLD as the hepatic component of the metabolic syndrome.   15 
 Indeed, in the last five years NAFLD has emerged as an independent risk factor for CVD.  16 
Several studies have observed increased carotid intima-media thickness (IMT) and carotid plaques 17 
in NAFLD patients, including children.(39, 107-111) Although there has been some conflicting 18 
work(112), a systematic review found that carotid plaques were 2 to 3 times more likely to be 19 
observed in NAFLD patients and IMT was strongly associated with NAFLD.(113)  Furthermore, 20 
multiple population studies have observed increased CVD events in NAFLD patients diagnosed by 21 
ultrasonography and demonstrated that the increased risk for CVD in NAFLD is independent of 22 
conventional risk factors and components of the metabolic syndrome.(114-116) These data add to 23 
population data where elevated liver enzymes have also been associated with increased risk for 24 
CVD.(67, 117)   25 
Essentially as the treatment of NAFLD involves correcting the same metabolic factors involved 26 
in CVD, it is prudent that all patients with NAFLD be evaluated for early atherosclerosis.  27 
Likewise, patients presenting with the metabolic syndrome or a high Framingham risk score(118) 28 
should be evaluated for the presence of NAFLD.  Children identified with NAFLD or the metabolic 29 
syndrome should be strongly counseled to avoid smoking, increase their physical activity and 30 
improve their nutrition in order to prevent the development of cardiovascular disease. 31 
 32 
 33 
The potential of systems biology 34 
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Systems biology is the study of a biological system (cell, tissue, organism) viewed as an 1 
integrated and interacting network of genes, proteins and biochemical reactions.  This methodology 2 
combines computational modeling with experimental biology in order to discover emergent 3 
properties that arise from studying a system as a whole; it is these properties that ultimately 4 
determine how a system is controlled or regulated.  In a systems approach one begins by 5 
constructing a predictive model from which a hypothesis is formed and then tested experimentally 6 
by perturbing the system.  Experimental techniques are generally the global approaches of 7 
genomics, proteomics and metabolomics.  Data obtained from these multiple approaches are 8 
integrated and compared to the original model, which is refined in an iterative process.  In the 9 
context of human health it is believed that systems biology is essential to future drug discovery and 10 
indeed, to a future of personalized, predictive and preventative medicine.(119)  In this vision, drug 11 
targets would be rational and identified through the analysis of normal and disease perturbed 12 
networks, while an individual could have their genome sequenced and in combination with 13 
extensive blood analyses would be able to obtain a “probabilistic future health history”.  Although 14 
systems biology is in its infancy and this vision still seems far off, global approaches have been 15 
applied to NAFLD and these datasets are relevant to the future creation of an integrated “systems” 16 
model of NAFLD. 17 
 Proteomic technologies are still evolving and analysis of a complete proteome, in the manner of 18 
DNA microarray analysis of complete genomes, has yet to be realized.  However, as disease 19 
biomarkers and drug targets are most likely to be proteins, proteomics is viewed as central to 20 
systems biology and key to predictive medicine.(120)  In the context of NAFLD, proteomic 21 
techniques have been used to analyze adipose(121), liver(122) and most recently serum(123) samples in 22 
NAFLD patients.  Ultimately it is most likely that a serum diagnostic or prognostic tool for 23 
NAFLD would be comprised of a panel of proteins, and this research highlights the power of 24 
systems methodologies for identifying candidate protein biomarkers. Significantly in the study by 25 
Bell and colleagues(123) their “potential biomarker panel” comprising of 6 proteins demonstrated 26 
greater diagnostic utility than ALT to differentiate between their patient groups. It is also 27 
noteworthy that Charlton(122) and Bell(123) independently identified lumican, a protein that activates 28 
transforming growth factor-beta and smooth muscle actin, elevated in both liver and serum from 29 
NASH patients.  These studies have given insight into NAFLD pathogenesis and have identified 30 
candidate disease biomarkers worthy of prospective validation.   31 
 32 
 33 
Conclusion 34 
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Non-alcoholic fatty liver disease is highly prevalent with an estimated 20-30% of the UK 1 
population effected.  Research on the natural history of NAFLD has demonstrated that even simple 2 
steatosis can not be considered benign as 47% of these patients will progress to NASH in 8-13 3 
years.  An estimated 25-50% of patients with NASH will progress to advanced fibrosis and 4 
cirrhosis.  In real numbers this is 300,000 to 1.8 million cases in the UK, 50% of whom will require 5 
a liver transplant to avoid death.  It is clear that a diagnosis of NAFLD is associated with increased 6 
risk of mortality from liver- and cardiovascular-related events and the British Liver Trust has 7 
demonstrated that liver disease is the only major cause of death still increasing yearly in the 8 
UK.(124)  An additional public health concern is the rising incidence of NAFLD in children who are 9 
not exempt from risk of cardiovascular disease, the need for liver transplants or early death.  Part of 10 
the challenge in assessing the burden of NAFLD in the population is the lack of a non-invasive 11 
screening test for NAFLD.   12 
While NAFLD incidence is strongly linked to insulin resistance and the metabolic syndrome, the 13 
development and progression of NAFLD involves a myriad of molecular and cellular events that 14 
are influenced by both genetic and environmental factors.  Determination of the critical factors 15 
involved in disease progression will identify possible therapeutic targets for treatment of NAFLD 16 
and may form the basis of prognostic tests. Proteomic studies are beginning to identify serum and 17 
liver proteins found altered in NAFLD. The modeling of NAFLD protein and gene regulatory 18 
networks in a systems biology fashion is most likely to yield diagnostic, prognostic and therapeutic 19 
targets for NAFLD and more research of this type is urgently needed.   20 
 21 
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Fig. 1. Progression of non-alcoholic fatty liver disease (NAFLD). 47% of patients presenting with 21 
steatosis progress to steatohepatitis and 25-50% of patients presenting with steatohepatitis develop 22 
fibrosis or cirrhosis within 8-13 years.(54) The 10 year prognosis for patients with NAFLD-related 23 
cirrhosis is very poor with 50% requiring a liver transplant, 20% dying of a liver-related cause and 24 
7% developing hepatocellular carcinoma.(56) Dashed lines indicate the potential for reversal. 25 
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Fig 2. Genetic and environmental factors associated with non-alcoholic fatty liver disease 17 
(NAFLD) development and progression.  Solid lines indicate that comorbidities (ovals) in addition 18 
to genetic and environmental factors influence the development and progression of NAFLD.  19 
Dashed lines show that genetic and environmental factors also influence the development of 20 
comorbid conditions. 21 
 22 
